Pulmonx Corporation LUNG
2.80 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
2.80 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
2.70 Day range 2.90
1.13 52-week range 3.25
- YTD
- +26.70%
- 1 year
- +44.33%
News
fool.com Pulmonx: 3 Key Takeaways for Long-Term Investors Pulmonx returned to top-line growth with $22.8 million in third-quarter revenue. Third-quarter operating expenses fell 18% year over year to $24.9 million.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…
benzinga.com Pulmonx Q3 2026 Earnings Call Transcript Pulmonx (NASDAQ:LUNG) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG)…
benzinga.com Pulmonx Q3 EPS $(0.19) Beats $(0.26) Estimate, Sales $22.835M Beat $21.944M Estimate Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.26) by 26.92 percent. This is a 44.12 percent increase over losses of $(0.34) per…
benzinga.com Pulmonx Affirms FY2026 Sales Guidance of $90.000M-$92.000M vs $90.608M Est Pulmonx (NASDAQ:LUNG) affirms FY2026 sales outlook from $90.000 million-$92.000 million to $90.000 million-$92.000 million vs $90.608 million estimate.